SETD2 is frequently inactivated through mutation and/or deletion in renal, bladder, and breast cancers.10, 14, 50 Lower expression of this gene in breast tumors correlated with poor overall survival (Figure 6). This evidence concerns the gene SETD2 and breast neoplasm.